Ligand Pharmaceuticals | LGND - Operating Expenses



Ligand Pharmaceuticals reported $40.46M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Amgen USD 6.52B 337M Jun/2025
Arrowhead Research USD 193.32M 31.81M Jun/2025
Baxter International USD 2.54B 29M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
Glaxosmithkline GBP 5.55B 1.87B Jun/2025
Insmed USD 361.29M 20.33M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
Ligand Pharmaceuticals USD 40.46M 41.09M Jun/2025
MacroGenics USD 59M 23.06M Jun/2025
Merck USD 9.44B 217M Jun/2025
Pacira USD 170.87M 3.93M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Veracyte USD 115.85M 2.54M Jun/2025